Working with Pharmaceutical Companies
The National Osteoporosis Society relies on donations to fund its work and partnerships with the pharmaceutical industry can help with the charity’s vision to create a brighter future for people with fragile bones. We are proud though to be an independent charity which represents the voice of people affected by osteoporosis and fragility fractures. As such we have a robust policy which states how we work with pharmaceutical companies:
- Any partnership must clearly support and align with our objectives. It must be in pursuit of our mission, with public good, patient benefit and welfare as the primary aims. The advantages must clearly outweigh the disadvantages.
- The charity will not recommend or explicitly endorse individual pharmaceutical products or treatments.
- All partnerships must comply with the code of practice for the pharmaceutical industry
- The level of income the charity receives from the pharmaceutical industry is capped at 15%
- We strive to abide by the principles of independence, integrity and openness. In order to preserve this we do not approve relationships designed to give one pharmaceutical company competitive advantage. Wherever possible we will seek a partnership composed of a minimum of two companies. Where this is not possible, each proposal will be assessed on a case-by-case basis.
Our annual income figure is published in our Financial Accounts.
A list of our Corporate Partners.